BACKGROUND: Recent data suggest that alcohol-related hepatocellular carcinoma (HCC) is diagnosed at a later stage. The aim of this study was to compare HCC characteristics and outcomes in an alcohol-related group (group A) and a non-alcohol-related group (group NA). METHODS: A total of 1207 patients with newly diagnosed HCC were prospectively included between May 2008 and October 2009. Patients with multiple causes (alcohol plus another cause) were excluded. Patients were followed every year for 5 years. Recorded variables, including etiologies were tested as prognostic factors of survival in a multivariate Cox model after adjustments for a lead-time bias. RESULTS: In all, 894 patients were analyzed: 582 (65.1%) were in group A, and 312 (34.9%) were in group NA. Alcohol-related HCC was more likely to be diffuse and detected in patients with a worse performance status and worse liver function. After adjustments for a lead-time bias, the median overall survival (OS) was 9.7 and 5.7 months in groups NA and A, respectively (P 5 .0002), and 5.8 and 5.0 months in alcohol-abstinent and alcohol non-abstinent groups, respectively (P 5 .09). The prognostic role of alcohol disappeared when survival was assessed at each Barcelona Clinic Liver Cancer ( 
INTRODUCTION
Liver cancer is the second leading cause of cancer-related deaths worldwide, 1 and hepatocellular carcinoma (HCC) accounts for more than 90% of all primary liver cancers. Its incidence has dramatically increased in Western countries during the past decades. 2 Most cases of HCC develop in the context of liver cirrhosis. 3 Worldwide, hepatitis B and C infections are the first 2 main causes of HCC. 4 Alcohol abuse and nonalcoholic fatty liver disease are the other 2 dominant risk factors for developing HCC, with different prevalence rates in different parts of the world. 3, 5 Because of improvements in the efficacy of hepatitis C virus and hepatitis B virus treatments and the increased alcohol per capita consumption in some regions (the World Health Organization [WHO] South-East Asia region and the WHO Western Pacific region), 6 it is likely that alcohol will become a leading cause of HCC in the near future. Excessive alcohol consumption (>80 g/d) over a period > 10 years increases the risk of HCC approximately 5-fold. 7 The annual incidence of HCC in patients with alcoholic liver cirrhosis is 1% to 2%. 5 In France, alcohol is a major cause of liver disease, and HCC accounts for more than 7000 deaths per year. 8, 9 Corresponding authors: Charlotte E. Recent retrospective studies suggest that the tumor stage at diagnosis is influenced by the etiology, with alcoholrelated HCC being diagnosed at a later stage. 10, 11 The CHANGH cohort (cohorte de Carcinomes Hepatocelulaires de l'Association des h epato-Gastroent erologues des Hôpitaux G en eraux) was a French prospective, observational cohort study that collected data on the clinical features and treatment allocations of patients with newly diagnosed HCC. In this cohort, alcoholrelated HCC was predominant. We took advantage of this large prospective cohort to compare the clinical features at diagnosis, the therapeutic allocations, and the outcomes of alcohol-related and non-alcohol-related HCC.
MATERIALS AND METHODS

Patients
Between May 1, 2008, and October 31, 2009, 103 hepatogastroenterology units in French hospitals participated in the CHANGH prospective study. The study was approved by the Ethic Committee Ile de France IX (Creteil, France), and written informed consent was obtained from all participants.
The inclusion criterion was HCC newly diagnosed on the basis of histological or radiological evidence. The radiological diagnosis was based on the Barcelona radiological criteria available during the inclusion period: 1) cirrhosis and a nodule (or nodules) 10 to 20 mm in diameter and 2 typical dynamic images, 2) cirrhosis and a nodule (or nodules) measuring > 20 mm and 1 typical dynamic image, 3) 1 image of suspected HCC plus an a-fetoprotein value > 200 ng/mL, or 4) cirrhosis plus an a-fetoprotein value > 400 ng/mL. 12, 13 Patients with a history of HCC were excluded. Underlying liver disease was considered to be alcohol-related if there was a history of chronic alcohol abuse, with an intake of alcohol > 40 g/day, according to the WHO definition 14 (see online supporting information for other etiologies). The status of alcohol consumption (abstinent or not abstinent according to the investigator's evaluation) was recorded at the time of diagnosis. Patients were considered to be involved in a cirrhosis follow-up program according to the investigator's statement.
Data from hepatic ultrasound, computed tomography, and magnetic resonance imaging were collected. The tumor size, number of nodules, and extrahepatic spread were analyzed, and the patients were classified with the Barcelona Clinic Liver Cancer (BCLC) scoring system. 14 Follow-up information, including the treatment allocation, was collected prospectively and annually for 5 years or until death.
Statistical Analysis
Continuous data are expressed as means and standard deviations, and discrete variables are expressed as absolute and relative frequencies. The Student t test and an analysis of variance (for parametric tests) or the Mann-Whitney U and Kruskal-Wallis tests (for nonparametric tests) were applied to compare continuous data in various groups. Categorical variables were compared with Pearson's chisquare test or Fisher's exact test.
The survival time was calculated from the date of the HCC diagnosis to the date of death or end of follow-up and was corrected for a lead-time bias. The lead time is the length of time between the detection of a case through screening and a diagnosis that would have normally happened in the absence of screening (on symptoms). To adjust for a lead-time bias, 2 methods were used, 15, 16 as proposed by Cucchetti et al 17 (for details, see online supporting information). Patients diagnosed with HCC during a cirrhosis follow-up program and those diagnosed outside one were used for the lead-time estimation. Under the assumption of a median tumor volume-doubling time of 90 days, 17, 18 the mean lead time was estimated to be 210 6 11.4 days, and the median was estimated to be 172 days (interquartile range [IQR], 106.0-287.0 days). A sensitivity analysis of the aggressiveness of the tumor was performed via the variation of the median tumor volume-doubling time: 2 analyses were performed with 50 and 120 days (vs 90 days in the baseline analysis).
Lead time-adjusted survival curves were plotted with the Kaplan-Meier method. Log-rank and GehanWilcoxon tests were used to compare survival rates between various groups. Univariate and multivariate Cox proportional hazards regression analyses were performed to determine the effects of various variables on survival. Variables with a P value < .20 in univariate analyses were included in the multivariate model after adjustments for potential confounding variables (age and sex). Moreover, potential interactions between age, sex, and the risk factor were tested and included in the multivariate model when they existed.
A 2-sided P value < .05 was considered statistically significant. The statistical analysis was performed with SPSS software (version 19.0; SPSS, Inc, Chicago, Illinois).
RESULTS
Alcohol-Related HCC in Comparison With Other Etiologies
A total of 1207 patients were enrolled in the CHANGH study. For the purpose of this study, 267 patients with mixed causes of liver disease (alcohol plus any other cause) Patient characteristics are detailed in Table 1 . HCC was detected during a cirrhosis follow-up program in 119 patients from group A (20.7%) and in 80 patients from group NA (25.9%; P 5 .075). The HCC diagnosis was based on histology in 290 patients (32.4%) and on radiology findings in 604 patients (67.6%) according to available guidelines during the inclusion period. 12, 13 All patients had at least 1 measurable tumor. Macrovascular invasion (30.4% vs 23.7%; P 5 .03) and diffuse HCC (18.3% vs 11.1%; P 5 .006) were more frequent in group A. The BCLC stage was evaluable in 740 patients (some data were missing for the Eastern Cooperative Oncology Group performance status [n 5 31], the Child Pugh score [n 5 120], and the metastatic status [n 5 7] ). The distribution of BCLC stages between groups A and NA differed, but the overall comparison did not reach statistical significance (P 5 .06; Table 1 ).
Treatment with a curative intent (resection, ablation, or liver transplantation) was less likely to happen in group A (n 5 92 [16.3%]) than group NA (n 5 81 [27.1%]; P < .0001; Table 1 ).
The median follow-up period was 5.7 months (IQR, 1.57-13.34 months) for group A and 8.3 months (IQR, 2.43-14.33 months) for group NA (P 5 .04). A total of 601 patients had died by the time of the final analyses on October 31, 2014. The lead timeadjusted median overall survival (OS) was 5.7 months (IQR, 1.5-16.0 months) in group A and 9.7 months (IQR, 3.2-26.7 months) in group NA (P 5 .0002).
Factors associated with lead time-adjusted survival in the univariate analysis are listed in Table 2 . Univariate survival curves are shown in Figure 1 . When testing possible interactions between age, sex, and the risk factor (alcohol vs no alcohol), we found that the effect of the risk factor on survival differed according to the age group and according to sex revealing significant interactions. Factors associated with survival in the multivariate analysis model that included interactions are presented in Table 3 . In a sensitivity analysis, when the tumor-doubling time was varied (50 and 120 vs 90 days), the difference in OS between groups A and NA remained statistically significant (Supporting Fig. 2A,B [see online supporting information]). Moreover, with the shorter tumor-doubling time, being involved in a cirrhosis follow-up program was an independent factor associated with survival in the multivariate analysis (hazard ratio, 1.365; 95% confidence interval, 1.03-1.81; data not shown).
By contrast, after stratification by BCLC stage, the lead time-adjusted survival was comparable between group A and group NA ( Fig. 2A-D) .
HCC in the Alcohol-Abstinent Group Versus the Alcohol-Non Abstinent Group
The alcohol group was split into 2 groups: patients who had abstained from alcohol (abstinent group A; n 5 305), with a median time of abstinence of 12 months (IQR, 3-60 months), and patients who had not abstained from alcohol (nonabstinent group A; n 5 244) at the time of the HCC diagnosis. The alcohol-consumption status (abstinent vs nonabstinent) was not specified for 33 patients, and these patients were excluded from the following analyses.
The parameters with a statistically significant difference in the nonabstinent group versus the abstinent group were as follows: a worse performance status (Eastern Cooperative Oncology Group performance status > 1, 51.7% vs 39.5%; P 5 .005), a later stage of HCC at diagnosis according to BCLC staging (P 5 .01), and fewer patients fulfilling the Milan criteria for liver transplantation (P 5 .04). The proportion of HCCs diagnosed during the cirrhosis follow-up program was lower in the nonabstinent group versus the abstinent group (11.9% vs 28.4%; P < .0001; Supporting Table 1 [see online supporting information]).
Intent-to-cure treatment was less frequent for the nonabstinent group A patients (n 5 32 [13.3%]) versus the abstinent group A patients (n 5 57 [19.5%]), but this difference was not statistically significant (P 5 .06). The lead time-adjusted median OS was 5.8 months for the abstinent group A patients (IQR, 1.7-19.5 months) and 5.0 months for the nonabstinent group A patients (IQR, 1.3-13.2 months; P 5 .09).
Importance of a Cirrhosis Follow-Up Program
One hundred ninety-nine HCCs were diagnosed during a cirrhosis follow-up program. The tumors diagnosed during a cirrhosis follow-up program were more likely to receive intent-to-cure treatments (15.4% vs 37.6%; P < .0001) than HCCs diagnosed outside a cirrhosis followup program (Supporting Table 2 [see online supporting information]). These observations were similar when the analysis considered only the alcohol groups (Supporting Table 3 [see online supporting information]).
In the whole study population (group A plus group NA), the lead time-adjusted median survival was 11.7 months (IQR, 4.0-30.5 months) among patients enrolled in a cirrhosis follow-up program and 5.4 months (IQR, 1.6-16.1 months) among patients with HCC diagnosed incidentally (P < .0001).
Among the 199 patients involved in a cirrhosis follow-up program, patients with alcohol-related HCC had shorter survival (9.7 months; IQR, 2.7-20.7 months) than patients with non-alcohol-related HCC (15.0 months; IQR, 6.7-34.1 months; P 5 .042). Patients with alcohol-related HCC were less likely to receive a treatment with curative intent (30.1% vs 49.3%; P 5 .008) than patients with non-alcohol-related HCC, although the tumor burden according to the BCLC stage was comparable (data not shown). Importantly, the survival times of abstinent group A patients and group NA patients involved in a cirrhosis follow-up program were similar (median OS, 11.7 and 15.7 months, respectively; P 5 .19), and they were significantly longer than the survival time observed for the nonabstinent group A patients (median OS, 7.6 months; P 5 .006; Fig. 3 ).
DISCUSSION
In our large prospective study, we show that in comparison with patients with non-alcohol-related HCC, patients with alcohol-related HCC had reduced OS, mainly because of worse liver function and tumor characteristics at diagnosis. Patients involved in a cirrhosis follow-up program had improved survival; this was especially true for alcohol-abstinent patients and nonalcoholic patients in comparison with nonabstinent patients.
Although alcohol is a dominant risk factor associated with HCC in certain parts of the world, 19, 20 specific clinical data on alcohol-related HCC are scarce. 10, 11 Various assumptions can be made to explain why patients with alcohol-related HCC have reduced survival Abbreviations: AFP, a-fetoprotein; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; group A, alcohol-related hepatocellular carcinoma group; group NA, non-alcohol-related hepatocellular carcinoma group; HCC, hepatocellular carcinoma; HR, hazard ratio; PAL, alkaline phosphatases. a Diffuse HCC, metastatic HCC, and/or macrovascular invasion.
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Cancer May 1, 2018 in comparison with patients with non-alcohol-related HCC: a diagnosis at a later stage due to lower rates of HCC screening, worse liver function and/or ongoing alcohol consumption preventing curative options, and discrimination against alcoholic patients leading to less aggressive treatment options. In our study, cirrhosis was unrecognized before the HCC diagnosis more frequently in alcoholic patients, and this confirmed a previous report. 21 Lack of a diagnosis of cirrhosis prevents the implementation of screening programs, which are associated with a diagnosis at an earlier stage, curative treatment, and improved survival. 18, [22] [23] [24] [25] However, in our study, the rates of implementation of a cirrhosis follow-up program were comparable in the 2 groups (<30%) and could not per se explain the difference in survival between them. Unfortunately, our case-report form did not provide accurate information on screening order rates and imaging timeframes, which might be different within the 2 groups. Singal et al 26 reported that screening for HCC was less likely in patients with alcohol abuse. The most common reason for a lack of screening was a failure to order surveillance in patients with known cirrhosis, especially patients with an alcoholic etiology. Furthermore, alcoholic patients are less likely to complete surveillance when ordered. 27 Importantly, Bucci et al 11 observed similar survival between alcoholic patients and patients with hepatitis C virus among patients undergoing HCC surveillance according to guidelines. The poorer prognosis of alcohol-related HCC is, therefore, very likely to be related to an advanced stage at diagnosis due to screening failure instead of greater cancer aggressiveness.
Interestingly, in our study, nonabstinent alcoholic patients had lower survival, even when we restricted the analysis to patients involved in a cirrhosis follow-up program. It has been shown that the management of chronic diseases can influence a patient's awareness of his or her addiction. 28, 29 Therefore, the diagnosis and management of alcohol cirrhosis could influence a patient's behavior toward alcohol consumption and ultimately improve his or her prognosis.
The severity of comorbidities or liver function and ongoing alcohol consumption might prevent the implementation of curative treatments in patients with HCC amenable to these options on the basis of tumor characteristics. Reasons for not listing patients for surgery or liver transplantation were not captured in our case-report form. However, the Child-Pugh score was independently associated with survival in the multivariate analysis. Even among patients with HCC diagnosed within a cirrhosis follow-up program, patients with an alcoholic etiology had higher rates of esophageal varices and higher Child Pugh scores, which could explain the fewer curative treatments and worse outcomes. Interestingly, when alcohol-abstinent patients were compared with nonalcoholic patients, the difference disappeared. An alcohol-consumption reduction could possibly reduce portal hypertension or improve liver function 30 and increase the chances for patients to qualify for curative options.
Finally, it has been reported that alcohol-dependent patients were being held more responsible for their condition than other people. 31 We cannot exclude that an alcoholic etiology could be associated with less consideration for more aggressive options.
Our study has some limitations. According to the selection criteria, the included patients had newly diagnosed HCC, but we cannot rule out missing inclusions. Most patients were issued from primary care centers, and this could have had an impact on treatment allocation. 32 However, the OS observed for the whole cohort (groups A and NA; median survival, 8.0 months) was in the same range as the survival reported by Goutte et al 20 in another French HCC population (median survival, 9.4 months). The greater proportion of alcohol-related HCC (65% vs 44% in Goutte et al) might explain the lower survival in our study. In addition, although it is an important prognostic factor in HCC, data on microvascular invasion were not available for analysis.
In conclusion, we show that patients with alcoholrelated HCC have reduced survival, mainly on account of a diagnosis at a later stage, because survival within each BCLC stage is comparable in the 2 populations. To improve the prognosis of HCC in the alcoholic population, efforts should be made to improve screening for cirrhosis and HCC as well as the management of alcohol abuse. A smaller tumor burden and better liver function at diagnosis should increase rates of patients with alcoholrelated HCC amenable to curative treatment.
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